Molnupiravir And Nirmatrelvir-Ritonavir Appeared To Have Clinical Benefit In Hospitalized Patients With Mild-To-Moderate COVID-19 Who Did Not Require Oxygen Therapy During Omicron BA.2 Wave, Study Shows

MedPage Today (8/26, Hein) reported, “During the Omicron BA.2 wave, antivirals molnupiravir and nirmatrelvir-ritonavir (Paxlovid) appeared to have clinical benefit in hospitalized patients with mild-to-moderate COVID-19 who did not require oxygen therapy,...